Diabetic kidney disease remains one of the leading causes of end-stage renal disease (ESRD) worldwide, and to date, no treatment can reverse existing kidney damage. Millions of patients live with declining renal function, and many eventually depend on dialysis or await a kidney transplant – options that manage the disease but don’t restore it.
One insult sits at the center of this decline: chronic hypoxia, or oxygen starvation, within kidney tissue. It’s a difficult target because the usual lever – blood flow – cuts both ways. Increasing renal perfusion mainly addresses downstream consequences, while decreased perfusion can actively worsen hypoxia. This is where Hyperbaric Oxygen Therapy (HBOT) has drawn growing research interest. By dramatically raising the amount of oxygen dissolved directly in blood plasma – independent of red blood cells or perfusion – HBOT offers a way to address tissue hypoxia without relying on increased blood flow.
HBOT is already an established, decades-old treatment for non-healing diabetic ulcers, and more recent trials have explored its effects on brain injury in both diabetic and non-diabetic patients. That track record has prompted researchers to ask a newer question: can the same mechanism help protect or support the diabetic kidney? In this article, we look at what the current – still early-stage – research says about HBOT’s potential role in renal health, kidney disease progression, and dialysis-related complications.
Understanding Renal Disorders
The kidneys are two bean-shaped organs responsible for filtering waste and excess fluid from the blood and producing urine. When the kidneys are damaged, they lose the ability to filter blood effectively. Because of a persistent shortage of organ donors and limited long-term treatment options, kidney disease remains a major global public health concern. Damage to the kidney’s filtering units — the nephrons — is what drives the progression of most kidney disorders.
Left unaddressed, kidney disease can progress to end-stage renal disease (ESRD), or complete kidney failure. Other common contributing conditions include malignant hypertension, hyperglycemia, and various glomerular, tubular, and interstitial disorders. Historically, ESRD has been managed with dialysis or kidney transplantation — but there’s a significant gap between the number of patients who need treatment and the resources available to treat them. Every year, a large number of patients die due to inadequate access to dialysis or a shortage of transplantable kidneys. This gap is exactly why the possibility of kidney tissue regeneration has drawn so much research attention.
Early Warning Signs of Kidney Disease
- Difficulty sleeping
- Loss of appetite
- Muscle cramps
- Swelling in the ankles and feet
- Frequent urination, especially at night
Signs that kidney failure may be progressing:
- Nausea and vomiting
- Reduced appetite
- Changes in urine output
- Anemia and fluid retention
- Elevated blood sugar (hyperglycemia)
- Pericardial inflammation
Can the Kidney Regenerate?
Kidney regeneration refers to the regrowth or repair of damaged renal structures to restore function. Because nephrons form only during embryonic development, adult humans cannot naturally grow new ones the way some tissues regenerate.
However, animal models have helped researchers understand nephrogenesis – the biological process behind new nephron formation – and human pluripotent stem cell research is expanding what’s understood about kidney development and repair.
Both diabetes and high blood pressure significantly raise the risk of kidney disease, and current treatment for kidney failure is still centered on dialysis or transplantation. Other kidney conditions include acute kidney injury, kidney cysts, kidney stones, and kidney infections.
End-Stage Renal Disease (ESRD) and Dialysis
ESRD is a condition in which the kidneys stop working permanently, requiring either a kidney transplant or ongoing dialysis to sustain life. Dialysis is a form of renal replacement therapy that uses external equipment to perform the blood-filtering work the kidneys can no longer do — removing excess water, waste products, and toxins.
Dialysis is used both for acute kidney injury (a sudden loss of kidney function) and chronic kidney disease (a slow, progressive decline, formerly referred to as ESRD), helping maintain a stable internal environment when the kidneys can’t. Globally, dialysis is the backbone of ESRD care — a disease burden driven mainly by diabetes mellitus (around 45% of cases) and hypertension (around 30%). The three main forms of dialysis are hemodialysis, peritoneal dialysis, and filtration-based therapies.
Hemodialysis: How It Works
Hemodialysis involves pumping blood through an external device that filters out waste and excess fluid before returning it to the body. It can be performed at home, in a hospital, or at a dedicated dialysis center. Most patients attend around three sessions per week, each lasting three to five hours, though more frequent, shorter sessions are also used in some care plans.
Before starting dialysis, most patients undergo a minor surgery to create an arteriovenous (AV) fistula — a direct connection between an artery and a vein, usually in the forearm. This allows a stronger, more consistent blood flow during treatment, so more blood can be filtered per session. When a fistula isn’t possible, an AV graft (a looped synthetic tube) can serve the same purpose. Common side effects of hemodialysis include low blood pressure, muscle cramps, and itching.
What the Research Says: HBOT and the Diabetic Kidney
Hyperbaric Oxygen Therapy (HBOT) involves breathing pure oxygen in a pressurized chamber — typically at pressures of around 2 to 3 atmospheres absolute (ATA) — which sharply increases the amount of oxygen dissolved directly in the blood and tissues. The Undersea and Hyperbaric Medical Society (UHMS) defines HBOT as treatment at or above 1.4 ATA, and most UHMS-approved protocols use a minimum of 2 ATA.
A 2015 study by Verma et al. examined whether HBOT could reduce diabetes-related kidney damage using db/db mice – a leptin-deficient rodent model of Type 2 diabetes. The researchers tracked several urinary biomarkers (NAG, NGAL, KIM-1, and Cystatin C) and found that 20 weeks of HBOT appeared to have a protective effect on renal tissue. Specifically:
- Cystatin C, a marker closely tied to tubular function and glomerular filtration rate, decreased with HBOT – suggesting reduced tissue damage in both the proximal tubules and glomeruli.
- NGAL (neutrophil gelatinase-associated lipocalin), a marker of ischemic and inflammatory kidney injury, also declined after HBOT, pointing to a possible repair effect on early-stage diabetic kidney damage in this animal model.
- Albumin-to-creatinine ratio, an indicator of glomerular membrane damage, was significantly lower in HBOT-treated mice (at 2.4 ATA) compared to untreated controls — consistent with protection of the glomerular filtration membrane in the kidney’s microvasculature.
The oxidative stress angle: In diabetic (db/db) mice, elevated glucose levels drive the mitochondria, endoplasmic reticulum, and NADPH oxidase enzymes to overproduce reactive oxygen species (ROS). This excess ROS fuels the chronic inflammation that can progress toward ESRD.
Interestingly, both hypoxia and HBOT can increase ROS production — a paradox the 2015 study’s authors addressed directly. Their proposed explanation: by restoring normal oxygen saturation in tissue, HBOT reduces the overload on the mitochondrial electron transport chain, which in turn lowers the pathological ROS generation associated with chronic hypoxia – even though HBOT itself introduces a temporary, controlled increase in oxygen-related ROS.
In other words, the therapy may improve mitochondrial function and tissue energetics in a way that supports healing, by allowing oxygen to reach damaged or diseased tissue more effectively.
HBOT and Calciphylaxis in Dialysis Patients
Calciphylaxis (calcific uremic arteriolopathy) is a rare, small-artery calcification disorder of uncertain cause that leads to painful skin lesions, which can progress to non-healing ulcers and gangrene. It’s seen almost exclusively in ESRD patients, with an estimated incidence of 1–4% among those on chronic hemodialysis.
In a small case series, five patients with calciphylaxis received HBOT – two on chronic hemodialysis and three on continuous ambulatory peritoneal dialysis (CAPD). Each received 25 to 35 sessions of HBOT at 2.5 ATA, 90 minutes per session. Two of the five patients experienced complete healing of their calciphylaxis lesions. Notably, most of these patients did not have uncontrolled hyperparathyroidism, which otherwise limits treatment options for this condition. While this is a very small sample, the findings suggest HBOT was well-tolerated and may be a reasonable adjunct option worth exploring further for calciphylaxis in dialysis patients.
Conclusion On HBOT Diabetic Kidney Disease
The evidence connecting Hyperbaric Oxygen Therapy to kidney health is still in its early stages — built mainly on animal studies and small case series rather than large human clinical trials. That said, the underlying rationale is sound: chronic hypoxia is a central driver of diabetic kidney disease, and HBOT is one of the few interventions that can meaningfully raise tissue oxygen levels without depending on increased blood flow, which is often what’s compromised in the first place.
What the current research suggests is a story worth continued investigation, not yet a confirmed treatment protocol. HBOT has decades of established use for diabetic ulcers and growing interest in neurological recovery – its extension into diabetic kidney disease and dialysis-related complications like calciphylaxis is a natural next question for researchers to pursue, and one that larger human trials will need to answer definitively. If you’re a diabetic or dialysis patient exploring adjunct therapies, this is a conversation worth having with your nephrologist – someone who can weigh your specific kidney function, comorbidities, and treatment history before considering any additional intervention.
FAQs On HBOT Diabetic Kidney Disease
1. Can Hyperbaric Oxygen Therapy cure kidney disease?
A. No. There is currently no treatment, including HBOT, that reverses established kidney damage or cures end-stage renal disease. Research on HBOT and kidney health is still early-stage, based mainly on animal studies and small patient samples, and it should not be viewed as a substitute for dialysis, transplantation, or nephrology-directed care.
2. How does HBOT relate to kidney hypoxia?
A. Chronic hypoxia (low tissue oxygen) is a key driver of diabetic kidney disease. HBOT increases the amount of oxygen dissolved directly in blood plasma, independent of blood flow, which is one reason researchers are studying its potential to address renal hypoxia specifically.
3. What did the 2015 Verma et al. study find?
A. Using a diabetic mouse model, the study found that 20 weeks of HBOT was associated with lower levels of kidney injury biomarkers (Cystatin C, NGAL) and a reduced albumin-to-creatinine ratio — findings consistent with a protective effect on kidney tissue in that animal model. It has not yet been confirmed in large-scale human trials.
4. Is HBOT used for dialysis patients specifically?
A. Some early research has looked at HBOT for calciphylaxis, a rare and serious skin condition seen in dialysis patients. In one small case series, 2 of 5 patients saw full healing of their lesions after a course of HBOT. This is a limited dataset, and any use in dialysis patients should be discussed with a treating physician.
5. Is Hyperbaric Oxygen Therapy safe?
A. HBOT is a well-established therapy for other approved conditions, such as non-healing diabetic ulcers, and is generally considered safe when administered under appropriate medical supervision in an accredited facility. As with any medical intervention, suitability depends on individual health status and should be assessed by a qualified physician.
6. Where can I learn more about HBOT in India?
A. For information on HBOT facilities, protocols, and approved indications in India, consult an accredited hyperbaric medicine provider or nephrologist who can assess your specific condition.
